Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. ...Show More
peer of
investor of
Metrics
marketSTOCKS
msh_idCOM:EDGEWISETX
localeus
websitehttps://edgewisetx.com
ipo_date2021-03-26
primary_stock_msh_idNASDAQ:EWTX
source_refb7ddb5b1-a23d-4b50-ac0a-02247b12e2ef
products_or_servicesNovel therapeutics for skeletal and cardiac muscle diseases, including EDG-7500 and sevasemten.